Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Short-term Investments (2021 - 2025)

Atara Biotherapeutics filings provide 5 years of Short-term Investments readings, the most recent being $8.0 million for Q3 2025.

  • On a quarterly basis, Short-term Investments fell 61.56% to $8.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.0 million, a 61.56% decrease, with the full-year FY2024 number at $146000.0, down 99.44% from a year prior.
  • Short-term Investments hit $8.0 million in Q3 2025 for Atara Biotherapeutics, up from $146000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $265.0 million in Q4 2021 to a low of $146000.0 in Q1 2022.
  • Median Short-term Investments over the past 5 years was $2.7 million (2022), compared with a mean of $48.3 million.
  • Biggest five-year swings in Short-term Investments: crashed 99.93% in 2023 and later surged 14102.74% in 2024.
  • Atara Biotherapeutics' Short-term Investments stood at $265.0 million in 2021, then tumbled by 43.44% to $149.9 million in 2022, then crashed by 82.73% to $25.9 million in 2023, then tumbled by 99.44% to $146000.0 in 2024, then skyrocketed by 5358.9% to $8.0 million in 2025.
  • The last three reported values for Short-term Investments were $8.0 million (Q3 2025), $146000.0 (Q4 2024), and $20.7 million (Q3 2024) per Business Quant data.